Anthracycline vs nonanthracycline adjuvant therapy for breast cancer

ONCOLOGY

Volumn 18, Issue 11, 2004, Pages 1367-1376

  Tack, Dina K ^a   Palmieri, Frances M ^b   Perez, Edith A ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CMF REGIMEN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METHODOLOGY; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHOTREXATE; PACLITAXEL;

EID: 16644377090     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998.
2. Chia SK, Speers CH, Bryce CJ, et al: Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 22:1630-1637, 2004.
3. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332:901-906, 1995.
4. Weiss RB, Woolf SH, Demakos E, et al: Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B. J Clin Oncol 21:1825-1835, 2003.
5. Engelsman E, Klijn JC, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial (10808). Eur J Cancer 27:966-970, 1991.
6. Adjuvant Therapy for Breast Cancer, National Institutes of Health Consensus Development Conference Statement, November 1-3, 2000. Available at http://consensus.nih.gov/cons/114/114_statement.htm. Accessed August 10, 2004.
7. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow up study in low-risk node-negative patients: Update of tamoxifen results (abstract 1). Proc Am Soc Clin Oncol 17:1a, 1998.
8. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990.
9. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:2651-2658, 1998.
10. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989.
11. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991.
12. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992.
13. Mauriac L, Durand M, Chauvergne J, et al: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. Ann Oncol 3:439-443, 1992.
14. Carpenter JT, Velez-Garcia E, Aron BS, et al: Five year results of a randomized comparison of cyclophosphamide, doxorubicin and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil for node positive breast cancer (abstract 68). Proc Am Soc Clin Oncol 13:66, 1994.
15. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14:35-45, 1996.
16. Misset JL, di Palma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996.
17. Pritchard K, O'Malley F, Andralis I, et al: Prognostic and predictive value of HER2/neu in a randomized trial comparing CMF to CEF in premenopausal women with axillary lymph node positive breast cancer (NCIC CTG MA.5) (abstract 165). Proc Am Soc Clin Oncol 21:42a, 2002.
18. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001.
19. Pritchard KI, Levine MN, Bramwell VHC, et al: A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. (abstract). Breast Cancer Res Treat 76(suppl 1):A17, 2002.
20. Perez EA, Suman VJ, Davidson NE, et al: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22:3700-3704, 2004.
21. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329, 2004.
22. Crump M, Tu D, Shepherd L, et al: Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3066-3071, 2003.
23. Smith RE, Bryant J, DeCillis A, et al: Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 21:1195-1204, 2003.
24. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 17:2355-2364, 1999.
25. Perez EA, Vogel CL, Irwin DH, et al: Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73:85-88, 2002.
26. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 21:588-592, 2003.
27. Green MC, Buzdar AU, Smith T, et al: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC: Final results of a prospective phase III randomized trial (abstract 135). Proc Am Soc Clin Oncol 21:35a, 2002.
28. Martin M, Pienkowski T, Mackey JR, et al: TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up (abstract). Breast Cancer Res Treat 82(suppl 1):A43, 2003.
29. Seidman AD, Berry D, Cirrincione C, et al: CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC (abstract 512). Proc Am Soc Clin Oncol 2004. Available online at www.asco.org. Accessed September 27, 2004.
30. Muss HB, Woolf SH, Berry DA, et al: Older women with node-positive breast cancer get similar benefits from adjuvant chemotherapy as younger patients: The Cancer and Leukemia Group B experience (abstract 11). Proc Am Soc Clin Oncol 21:4a, 2003.
31. Venturini M, Aitini E, Del Mastro L, et al: Phase III adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO MIG1 study (abstract). Breast Cancer Res Treat 82(suppl 1):A12, 2002.
32. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003.
33. Jones S, Savin A, Asmar F, et al: Three year results of a prospective randomized trial of adjuvant chemotherapy for patients (pts) with stage I-III operable, invasive breast cancer comparing 4 courses of doxorubicin/cyclophosphamide (AC) to 4 courses of docetaxel/ cyclophosphamide (TC) (abstract 59). Proc Am Soc Clin Oncol 22:15, 2003.
34. Perez EA, Hillman DW, Stella PJ, et al: A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 88:124-131, 2000.
35. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
36. Brufsky A, Cleary D, Fuchs C, et al: First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and traztuzumab (H) (TCH): A phase II trial (abstract 71). Proc Am Soc Clin Oncol 22:18, 2003.
37. Albain KS, Nag S, Calderillo-Ruiz G, et al: Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival (abstract 510). Proc Am Soc Clin Oncol 22:14S, 2004.
38. Aas T, Borresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996.
39. Paik S, Bryant J, Tan-Chiu E, et al: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998, 2000.
40. Muss HB, Thor AD, Berry DA, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
41. Thor AD, Berry DA, Budman DR, et al: erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 90:1346-1360, 1998
42. Paik S, Bryant J, Park C, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370, 1998.
43. Ravdin PM, Green S, Albain KS, et al: Initial report of the SWOG biological correlative study of c-erb-B-2 expression as a predictor of outcome in a trial comparing adjuvant CAFT with tamoxifen (T) alone (abstract 374). Proc Am Soc Clin Oncol 17:97a, 1998.
44. Konecny GE, Thomssen C, Luck HJ, et al: Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96:1141-1151, 2004.
45. Jarvinen TA, Tanner M, Rantanen V, et al: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847, 2000
46. Di Leo A, Chan S, Friedrichs K, et al: Biological markers (BM) with predictive value in metastatic breast cancer (MBC) patients (pts) randomly treated with doxorubicin (A) or docetaxel (D) (abstract 213). Proc Am Soc Clin Oncol 21:54a, 2002.